@article{oai:nagasaki-u.repo.nii.ac.jp:00002149,
 author = {Yoshida, Masataka and Takazono, Takahiro and Tashiro, Masato and Saijo, Tomomi and Morinaga, Yoshitomo and Yamamoto, Kazuko and Nakamura, Shigeki and Imamura, Yoshifumi and Miyazaki, Taiga and Sawai, Toyomitsu and Nishino, Tomoya and Izumikawa, Koichi and Yanagihara, Katsunori and Mukae, Hiroshi and Kohno, Shigeru},
 issue = {21},
 journal = {Internal Medicine},
 month = {Nov},
 note = {Streptococcal toxic shock syndrome caused by group B streptococcus (GBS) is a rare, but lethal disease. We experienced a 45-year-old woman with pustular psoriasis who developed toxic shock-like syndrome during infliximab treatment. Surprisingly, similar episodes recurred three times in one year with restarting of infliximab treatments. In the third episode, GBS were detected in blood, urine, and vaginal secretion cultures. These episodes of shock syndrome were possibly due to GBS. To the best of our knowledge, this is the first case report of recurrent streptococcal toxic shock syndrome possibly caused by GBS which was induced by anti-TNF-α inhibitor therapy. The restarting of biological agents in patients with a history of toxic shock syndrome should therefore be avoided as much as possible., Internal Medicine, 55(21), pp.3211-3214; 2016},
 pages = {3211--3214},
 title = {Recurrent Streptococcus agalactiae Toxic Shock Syndrome Triggered by a Tumor Necrosis Factor-α Inhibitor},
 volume = {55},
 year = {2016}
}